热灭活(灭活生物体），NR-1_Vaccinia virus

NR-56495??SARS-Related Coronavirus 2, Isolate hCoV-19/USA/GA-EHC-2811C/2021 (Lineage B.1.1.529; Omicron Variant), Heat Inactivated(Inactivated Organisms)|SARS-Related Coronavirus 2|Isolate hCoV-19/USA/GA-EHC-2811C/2021 (Lineage B.1.1.529; Omicron Variant), Heat Inactivated| -60°C or colder |M SutharAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/USA/GA-EHC-2811C/2021 (Lineage B.1.1.529; Omicron Variant), Heat Inactivated, NR-56495."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. Due to the high volume of orders, NIAID will prioritize shipments. NR-56495 is a preparation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/GA-EHC-2811C/2021 that has been inactivated by heating to 65°C for 30 minutes and diluted prior to vialing. SARS-CoV-2, isolate hCoV-19/USA/GA-EHC-2811C/2021 was isolated from a mid-turbinate swab from a vaccinated patient with travel history from Africa/South Africa on December 1, 2021, in Georgia, USA. Each vial contains approximately 0.25 mL of heat inactivated, clarified and diluted cell lysate and supernatant from Homo sapiens lung adenocarcinoma epithelial cells (Calu-3; ATCC ^? HTB-55?) infected with SARS-CoV-2, isolate hCoV-19/USA/GA-EHC-2811C/2021. The vial should be centrifuged prior to opening. Note: The long-term stability of this preparation is not known at this time. It is recommended that users confirm the activity of the product if not used within three months of receipt. You may also contact BEI Resources for updated stability information.

NR-56128?? SARS-Related Coronavirus 2, Isolate hCoV-19/USA/MD-HP05285/2021 (Lineage B.1.617.2; Delta Variant), Heat Inactivated(Inactivated Organisms)|SARS-Related Coronavirus 2|SARS-Related Coronavirus 2, Isolate hCoV-19/USA/MD-HP05285/2021 (Lineage B.1.617.2; Delta Variant), Heat Inactivated|-60°C or colder|AS PekoszAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/USA/MD-HP05285/2021 (Lineage B.1.617.2; Delta Variant), Heat Inactivated, NR-56128."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. NR-56128 is recommend for molecular assays. The current quality control testing for this item does not include immunological assays and it is not recommended that NR-56128 be used in this manner. NR-56128 is a preparation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/MD-HP05285/2021 that has been inactivated by heating to 65°C for 30 minutes and diluted prior to vialing. SARS-CoV-2, isolate hCoV-19/USA/MD-HP05285/2021 was isolated from a human in Maryland, USA on April 26, 2021. The complete genome of the clinical isolate of SARS-CoV-2, hCoV-19/USA/MD-HP05285/2021 has been sequenced (GISAID: EPI_ISL_2103264).

Intended Use: NR-56128 is primarily intended for use in molecular assays or can be used as a process (work-flow) control (for example: viral RNA extraction through qPCR amplification process). Please refer to the Certificate of Analysis for pre-inactivation infectious titer and post-inactivated genome equivalence (GE) quantification by Droplet Digital PCR for your specific lot. The GE is determined by full and partial genomes and is an estimate for end-users to qualify assays on their platform and is subject to efficiency of RNA extraction. The estimated GE can also be used to make a dilution series to estimate level of detection. The heat inactivation procedure is known to damage viral RNA and large fragments are not easily amplified. The suitability of this product as a whole cell antigen preparation has not been assessed and may be influenced by the protein content largely contributed by the host cell and the fetal bovine serum used during virus propagation.

Inactivation Procedure: Please refer to the Certificate of Analysis for the inactivation testing details. Each vial contains approximately 0.25 mL of heat inactivated, clarified and diluted cell lysate and supernatant from Homo sapiens lung adenocarcinoma epithelial cells (Calu-3; ATCC ^? HTB-55?) cells infected with SARS-CoV-2, isolate hCoV-19/USA/MD-HP05285/2021. The vial should be centrifuged prior to opening. Note: The long-term stability of this preparation is not known at this time. It is recommended that users confirm the activity of the product if not used within three months of receipt. You may also contact BEI Resources for updated stability information.

NR-55245??SARS-Related Coronavirus 2, Isolate USA/CA_CDC_5574/2020, Heat Inactivated(Inactivated Organisms)|SARS-Related Coronavirus 2|Isolate USA/CA_CDC_5574/2020, Heat Inactivated|-60°C or colder|CDCAcknowledgment for publications should read "The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA/CA_CDC_5574/2020, Heat Inactivated, NR-55245."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. NR-55245 is recommend for molecular assays. The current quality control testing for this item does not include immunological assays and it is not recommended that NR-55245 be used in this manner. NR-55245 is a preparation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate USA/CA_CDC_5574/2020 that has been inactivated by heating to 65°C for 30 minutes and diluted prior to vialing. SARS-CoV-2, isolate USA/CA_CDC_5574/2020 was isolated from a nasopharyngeal swab on December 29, 2020 in San Diego County, California, USA. Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate USA/CA_CDC_5574/2020 is assigned lineage B.1.1.7 and GISAID clade GR using Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN) tool. The complete genome of SARS-CoV-2, isolate USA/CA_CDC_5574/2020 has been sequenced (GISAID: EPI_ISL_751801). Intended Use: NR-55245 is intended for use in molecular assays or can be used as a process (work-flow) control (for example: viral RNA extraction through qPCR amplification process). Please refer to the Certificate of Analysis for pre-inactivation infectious titer and post-inactivated genome equivalence (GE) quantification by Droplet Digital PCR for your specific lot. The GE is determined by full and partial genomes and is an estimate for end-users to qualify assays on their platform. The quantified products can also be used to make a dilution series to estimate level of detection. However, this product is not suitable as a whole cell antigen preparation because the protein content is largely contributed by the host cell and the fetal bovine serum used during virus propagation. Inactivation Procedure: Please refer to the Certificate of Analysis for the inactivation testing for the lot of material you have obtained from BEI Resources. In brief, 10% of the lot of inactivated virus is tested to confirm the absence of residual live virus by inoculating host cells. Using suitable controls, the test sample is passaged twice, with each passage incubated for two weeks. During procedure development, the inactivation protocol was validated by testing 100% of the sample of three independent lots for residual live virus. Note: The heat inactivation procedure is known to damage viral RNA and large fragments are not easily amplified. This material is suitable for qPCR assays for detection of small genome fragments. Each vial contains approximately 0.25 mL of heat inactivated, clarified and diluted cell lysate and supernatant from Vero E6 cells infected with SARS-CoV-2, isolate USA/CA_CDC_5574/2020. The vial should be centrifuged prior to opening. Note: The long-term stability of this preparation is not known at this time. It is recommended that users confirm the activity of the product if not used within three months of receipt. You may also contact BEI Resources for updated stability information.

NR-53530??Human Coronavirus, NL63, Heat Inactivated(Inactivated Organisms)|Human Coronavirus|NL63, Heat Inactivated|-60°C or colder|L van der HoekAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Human Coronavirus, NL63, Heat Inactivated, NR-53530."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. NR-53530 is a preparation of human coronavirus (HCoV), NL63 that has been inactivated by heating to 65°C for 30 minutes and diluted prior to vialing. HCoV, NL63 was isolated in 2003 from nasopharyngeal aspirate of human infant with acute respiratory disease in Amsterdam. The complete genome of HCoV, NL63 has been sequenced (GenBank: AY567487). Each vial contains approximately 0.25 mL of heat inactivated, clarified and diluted cell lysate and supernatant from Macaca mulatta kidney epithelial cells infected with HCoV, NL63. The vial should be centrifuged prior to opening. Note: The long-term stability of this preparation is not known at this time. It is recommended that users confirm the activity of the product if not used within three months of receipt. You may also contact BEI Resources for updated stability information.

NR-52286?? SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Heat Inactivated(Inactivated Organisms)|SARS-Related Coronavirus 2|SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Heat Inactivated|-60°C or colder|CDCAcknowledgment for publications should read "The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Heat Inactivated, NR-52286."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. NR-52286 is recommend for molecular assays. The current quality control testing for this item does not include immunological assays and it is not recommended that NR-52286 be used in this manner. NR-52286 is a preparation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate USA-WA1/2020 that has been inactivated by heating to 65°C for 30 minutes and diluted prior to vialing. SARS-CoV-2, isolate USA-WA1/2020 was isolated from an oropharyngeal swab from a patient with a respiratory illness who had recently returned from travel to the affected region of China and developed clinical disease (COVID-19) in January 2020 in Washington, USA. The complete genome of SARS-CoV-2, USA-WA1/2020 has been sequenced from the isolate (GISAID: EPI_ISL_404895) and after one passage in Vero cells – GenBank: MT020880). The complete genome of SARS-CoV-2, USA-WA1/2020 has been sequenced after four passages in Vero cells in collaboration with Database for Reference Grade Microbial Sequences (FDA-ARGOS; GenBank: MT246667). Intended Use: NR-52286 is primarily intended for use in molecular assays or can be used as a process (work-flow) control (for example: viral RNA extraction through qPCR amplification process). Please refer to the Certificate of Analysis for pre-inactivation infectious titer and post-inactivated genome equivalence (GE) quantification by Droplet Digital PCR for your specific lot. The GE is determined by full and partial genomes and is an estimate for end-users to qualify assays on their platform and is subject to efficiency of RNA extraction. The estimated GE can also be used to make a dilution series to estimate level of detection. The heat inactivation procedure is known to damage viral RNA and large fragments are not easily amplified. The suitability of this product as a whole cell antigen preparation has not been assessed and may be influenced by the protein content largely contributed by the host cell and the fetal bovine serum used during virus propagation.   Inactivation Procedure: Please refer to the Certificate of Analysis for the inactivation testing details.  Each vial contains approximately 0.25 mL of heat inactivated, clarified and diluted cell lysate and supernatant from Vero E6 cells infected with SARS-CoV-2, isolate USA-WA1/2020. The vial should be centrifuged prior to opening. Note: The long-term stability of this preparation is not known at this time. It is recommended that users confirm the activity of the product if not used within three months of receipt. You may also contact BEI Resources for updated stability information.

NR-50171??Middle East Respiratory Syndrome Coronavirus, EMC/2012, Heat-Inactivated(Inactivated Organisms)|Middle East Respiratory Syndrome Coronavirus|EMC/2012, Heat-Inactivated|-60°C or colder|RAM Fouchier, BL HaagmansAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Middle East Respiratory Syndrome Coronavirus, EMC/2012, Heat-Inactivated, NR-50171."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. NR-50549, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), EMC/2012, Irradiated Infected Cell Lysate, is in stock and may be a substitute for NR-50171. NR-50171 is a preparation of Middle East Respiratory Syndrome Coronavirus (MERS-CoV), EMC/2012 that has been inactivated by heating to 65°C for 30 minutes. MERS-CoV, EMC/2012 was isolated in 2012 from an elderly man with fatal pneumonia in Saudi Arabia. The complete genome of MERS-CoV, EMC/2012 has been sequenced (GenBank: JX869059). Each vial contains approximately 0.25 mL of heat inactivated, clarified cell lysate and supernatant from Vero E6 cells infected with MERS CoV, EMC/2012. The vial should be centrifuged prior to opening. Note: The long-term stability of this preparation is not known at this time. It is recommended that users confirm the activity of the product if not used within three months of receipt. You may also contact BEI Resources for updated stability information.